Is Zimmer Biomet Holdings, Inc. (ZBH) a good stock to buy?

Olyth's institutional analysis of ZBH reveals an Altman Z-Score of 1.70 and a Piotroski F-Score of 7/9. These metrics, combined with its 5-year revenue trend ($8.23B most recent), help investors decide if ZBH fits their risk profile.

What is the current P/E ratio for ZBH?

As of the latest trading session, Zimmer Biomet Holdings, Inc. (ZBH) has a trailing P/E ratio of 25.56.

Who is the CEO of Zimmer Biomet Holdings, Inc.?

The current Chief Executive Officer of Zimmer Biomet Holdings, Inc. is Ivan Tornos.

What was ZBH's revenue for the last 5 years?

According to its latest income statements, Zimmer Biomet Holdings, Inc. reported annual revenues of $8.23B (2025), $7.68B (2024), $7.39B (2023), $6.94B (2022), $6.83B (2021) respectively.

Does ZBH pay a dividend?

Zimmer Biomet Holdings, Inc. currently pays a dividend to its shareholders, with a trailing dividend yield of 1.05%.

How much debt and cash flow does ZBH have?

In its latest reporting period, Zimmer Biomet Holdings, Inc. generated $1.47B in Free Cash Flow against a total debt load of $7.52B.

What is the Price-to-Book (P/B) ratio of Zimmer Biomet Holdings, Inc.?

The Price-to-Book (P/B) ratio for Zimmer Biomet Holdings, Inc. (ZBH) is currently 1.42.

What is the Price-to-Sales (P/S) ratio of ZBH?

Based on trailing twelve-month data, Zimmer Biomet Holdings, Inc. (ZBH) trades at a Price-to-Sales (P/S) ratio of 2.20.

What is Zimmer Biomet Holdings, Inc.'s Return on Equity (ROE)?

Zimmer Biomet Holdings, Inc. (ZBH) has a Return on Equity (ROE) of 5.60%, representing its profitability relative to shareholder equity.

ZBH

Zimmer Biomet Holdings, Inc. · Healthcare

91.40

0.44%(+0.40)

93.63

2.44%(+2.23)

After Hours

Last Updated: — ET

52W L: $84.5952W H: $108.29

$91.61

CHG-1.39 (-1.49%)

H$95.31

L$85.76

VOL36M

ZBH (1h)

Company Profile

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Sector

Healthcare

Industry

Medical - Devices

Employees

17,000

IPO Date

2001-07-25

Beta

0.61

Websitewww.zimmerbiomet.com↗

ZBH

Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer

Aberdeen Group plc Trims Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Head-To-Head Analysis: SNDL (NASDAQ:SNDL) and Zimmer Biomet (NYSE:ZBH)

First Community Trust NA Sells 7,050 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Recommendation of “Hold” by Analysts

SG Americas Securities LLC Purchases 42,352 Shares of Zimmer Biomet Holdings, Inc. $ZBH